Nicole, as you think about where prediction markets are today and where they'll be in the future, what do you think the total addressable TAM is. Because you can financialize and issue contracts for a wide variety. We've talked about economics, there's obviously sports betting, there's culture markets, mention markets, the list goes on and on, but where do you think the end state is.What do prediction markets look like in a mature state. >> You know, it's interesting. I I think that the total addressable ma ...

Core Insights - Tesla CEO Elon Musk hinted at a new model potentially in development following a social media interaction, suggesting it could be "way cooler than a minivan" [2][4] Group 1: New Model Speculation - A user on social media prompted Musk about a Tesla minivan, to which he responded with a hint of an upcoming model [2] - Leaked images of a vehicle frame, resembling a minivan silhouette, have surfaced, possibly indicating the new model Musk referenced [3][4] Group 2: Sales Performance - Tesla's sales in Europe increased by 29% in February, with 13,740 vehicles registered, indicating strong demand [4] - The introduction of a new model could enhance customer choice and increase showroom traffic, addressing concerns about Tesla's aging vehicle lineup [5] Group 3: Strategic Focus - Tesla has discontinued the premium Model S and Model X to concentrate on the Optimus humanoid robot, as stated by Musk during the Q4 earnings call [6] - The Cybertruck was introduced in 2023, marking a shift in Tesla's product offerings [6] Group 4: Market Performance - Tesla's stock price increased by 0.57% to $383.03 at market close, with a further rise of 0.97% to $386.71 in after-hours trading [6]

Core Insights - Craneware has reported a positive first half for fiscal '26, highlighting its ability to navigate changes in the industry successfully [1] - The company maintains a strong financial position with $184 million in Annual Recurring Revenue (ARR) and over 100% Net Revenue Retention (NRR) [2] - Approximately 90% of Craneware's revenue is recurring, indicating a stable and profitable business model [3] Financial Performance - The company has demonstrated strong financial performance, with significant progress across key metrics and sales performance, including competitive wins [4] - Craneware is profitable and generates cash, reflecting a solid operational performance in addition to financial results [3] Market Position - The company has established long-term relationships with customers, averaging 5 years, with some relationships exceeding 20 years [2] - There is an ongoing evolution and growth of Craneware's product set, contributing to an acceleration in its Total Addressable Market (TAM) [4]

Group 1 - The company identifies a $1 trillion Total Addressable Market (TAM), primarily focused on the top 1,000 advertisers [1] - Over the past 15 years, the company has primarily serviced S&P 500 and Fortune 500 brands [1] - The upcoming years are characterized as a recalibration year in 2025 and a disciplined reinvestment year in 2026 [1]

Core Insights - The year 2026 is characterized as a 'new chapter' for the company, with AI investments shifting from experimental to having measurable financial impacts [1] - The acquisition of Base 44 has significantly expanded the company's Total Addressable Market (TAM) by moving into the broader software application space beyond website building [1] - Wix Harmony is enhancing conversion and monetization by integrating visual editing with Vibe coding through a unified AI layer [1] Financial Performance - Base 44 achieved approximately $100,000,000 in Annual Recurring Revenue (ARR) just nine months after the acquisition, with new user acquisition reaching nearly two-thirds of the core Wix platform's volume [1] - The core business demonstrated strong performance with a net revenue retention rate of 105%, despite challenges from macro-driven Gross Payment Volume (GPV) affecting small and medium-sized businesses (SMBs) [1] Strategic Direction - The company is experiencing a strategic shift towards higher-tier subscriptions and business-oriented solutions, which have increased as a share of the total mix in 2025 [1] - The rapid, organic adoption of Base 44 by enterprise-sized organizations is attributed to the platform's capability in building customized CRM, ERP, and workflow tools without requiring a dedicated sales team [1]

Core Opportunity and Financial Performance - The company has a total addressable market (TAM) exceeding $3 billion, with significant opportunities in products like Hyalofast and Cingal [1][5] - Anika reported positive EBITDA of approximately $5 million and over $11 million in operating cash flow for 2025, supported by a strong balance sheet with more than $50 million in cash and no debt [2][5] Product Portfolio and Market Strategy - Anika has focused on hyaluronic acid (HA) technologies for 33 years, primarily in osteoarthritis pain management and regenerative medicine, generating strong profitability and cash flow [2][3] - The core products, Orthovisc and Monovisc, provide long-lasting pain relief and are characterized as high molecular weight products, contributing significantly to free cash flow [6][7] Revenue Channels and Growth Outlook - The revenue mix is divided between the OEM channel, which faces pricing pressure and is expected to be flat to modestly lower in 2026, and the commercial channel, which is projected to grow in the mid-teens with guidance of 10-20% growth for 2026 [4][15] - The commercial channel has shown consistent growth, increasing from $26 million in 2021 to $48 million in 2025, with expectations for continued growth driven by international OA pain products and the U.S. regenerative business [15] Regulatory and Pipeline Developments - Cingal, a combination product, has completed three Phase 3 trials and is expected to file for NDA submission with the FDA after completing necessary studies [13][14] - The Integrity Implant System, launched in 2023, generated about $2 million in sales in 2024 and is expected to reach approximately $6 million in 2025, exceeding initial expectations [9][8] Competitive Landscape and R&D Focus - Anika is focused on R&D investments related to Cingal and other pipeline products, aiming to differentiate its offerings in a competitive HA market [17] - The company is in discussions with the FDA regarding its PMA submission for Hyalofast, which has over 15 years of clinical data and is positioned as a single-stage surgery product [12][10]

Core Viewpoint - PROCEPT BioRobotics Corp. reported disappointing financial results for Q4 2025, leading to a decline in share price during premarket trading [1] Financial Performance - Total revenue for Q4 2025 was $76.4 million, a 12% increase year-over-year, but below the consensus estimate of $94.14 million [2] - U.S. handpiece and consumable revenue reached $34.0 million, up 16%, while U.S. system revenue was flat at $27.6 million compared to the previous year [2] - The company reported a loss of 53 cents per share, missing the consensus loss estimate of 32 cents [3] - Gross margin decreased to 61%, down from 64% in the same period last year, primarily due to lower-than-expected U.S. consumables revenue and a one-time expense [3] Operational Highlights - The company achieved its highest procedure volume to date with approximately 12,200 procedures and sold 65 new systems in Q4 2025 [4] Guidance and Future Outlook - PROCEPT BioRobotics expects first quarter 2026 sales between $79 million and $82 million, below the consensus of $92.65 million [6] - The company has lowered its fiscal 2026 sales guidance from $410 million-$430 million to $390 million-$410 million, while projecting U.S. procedure growth between 39% and 48% [6] - CEO Larry Wood indicated that handpiece unit sales and procedure volumes are expected to be closely aligned moving forward, impacting projected handpiece revenue guidance [5] Analyst Perspective - William Blair noted that the stock is trading at approximately 2x its updated 2026 sales estimate, suggesting it is undervalued given the potential for market expansion and leadership in medical devices [7] - Analyst Brandon Vazquez expressed a cautious but positive outlook, recommending buying the stock on weakness while maintaining an Outperform rating [8] Technical Analysis - The stock is currently trading 21.88% below its 20-day simple moving average and 32.5% below its 100-day simple moving average, indicating significant short-term weakness [10] - The Relative Strength Index (RSI) is at 44.45, suggesting neutral territory, while the absence of MACD data limits insights into momentum trends [11] Price Action - PROCEPT BioRobotics shares were down 26.33% at $20.51 during premarket trading, reaching a new 52-week low [12]

Core Insights - DraftKings shares are under downward pressure, with expectations for management to discuss the DraftKings Predictions initiative and medium-term financial targets [1] - The company is anticipated to provide insights into the total addressable market (TAM) for prediction markets, along with updated TAM for online sports betting (OSB) and iGaming, and revised revenue and profitability outlooks through 2028 and potentially 2030 [1][2] Revenue and EBITDA Estimates - Previous FY28 targets included $7.1 billion in revenue and $2.1 billion in EBITDA, with expectations that the revenue outlook may be raised to approximately $8.5 billion–$9.1 billion, including around $8.2 billion from core sports betting and about $650 million from prediction market fees [3] - EBITDA expectations for 2028 could be revised lower to around $1.5 billion–$1.7 billion, with approximately $1.5 billion from the core business and $100 million–$150 million from Predictions [4] Total Addressable Market Growth - The total addressable market for prediction markets is estimated to potentially reach $1.3 trillion in total volume, with projections for the market to grow to around $600 billion by 2028, and DraftKings potentially capturing 10%–20% of that share [5] - The company is expected to focus on long-term growth opportunities and the advantages of operating a vertically integrated exchange, despite a steeper near-term J-curve [6]

Core Insights - The company anticipates a growth deceleration from 27% to 13% in 2025 due to changes in consumer sentiment and macroeconomic challenges affecting the pet food sector [1] Company Strategy - The company has shifted its commercial framework to 'super-serve' Most Valuable Players (MVPs), who now account for 71% of net sales, by focusing on digital-forward media and streaming [1] - Operational agility is highlighted through controlled capacity expansion and the introduction of a breakthrough manufacturing technology aimed at enhancing quality, throughput, and yields [1] Market Positioning - Freshpet has increased its market share to 4% of the U.S. dog food segment, despite facing significant competition from new entrants in both brick-and-mortar and direct-to-consumer channels [1] - The strategic positioning now emphasizes an omnichannel approach, utilizing the existing fridge network and brand equity to engage consumers across retail, click-and-collect, and digital platforms [1] Market Potential - The Total Addressable Market (TAM) has been revised upward to 36 million households, driven by a generational shift towards younger consumers who prioritize high-quality pet nutrition [1]

Group 1: Market Outlook - Bank of America Securities analyst Vivek Arya has raised the total addressable market (TAM) estimate for AI data-center systems to $1.4 trillion by 2030, up from the previous estimate of $1.2 trillion [2] - The broader data-center systems market is expected to accelerate in 2026, with overall systems growth projected at 64% year-over-year, while AI systems are anticipated to grow by 100% YoY due to new accelerator deployments [2] Group 2: Supply and Margin Insights - Arya downplayed near-term supply risks, indicating that most of the expected 2026 High-Bandwidth Memory (HBM) supply growth (~75% Y/Y) and Chip-on-Wafer-on-Substrate (CoWoS) supply growth (~70% Y/Y) have already been allocated and secured from the previous year [3] - AI accelerator vendors are expected to pass on rising HBM/DDR costs to customers, which will help maintain margins as volume and system sales scale [3] Group 3: Company-Specific Implications - Nvidia Corp (NASDAQ:NVDA) is highlighted for its strong position, with $0.5 trillion in sales visibility through 2026, and revenue estimates have been raised by 7% for fiscal 2027, 2% for fiscal 2028, and 2% for fiscal 2029 [4] - Earnings per share (EPS) estimates for Nvidia have been increased by 8%, 3%, and 3% for the same fiscal periods [4] - Marvell Technology Inc. (NASDAQ:MRVL) has had its revenue estimates adjusted post-XConn acquisition, with expectations of healthy growth in Trn3 and 800G/1.6T optics through fiscal 2027, although visibility on next-gen programs remains limited until calendar 2027 [5]